Cargando…

Cost-benefit analysis of the integrated pharmaceutical supply chain information service after the establishment of the Korean Pharmaceutical Information Service

Background: The Korean Pharmaceutical Information Service (KPIS) was established in October 2007 to increase the transparency of the pharmaceutical supply chain by integrating relevant information. This study aimed to describe the KPIS program and perform a cost-benefit analysis of the KPIS. Methods...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Myojeong, Lee, GeunWoo, Hwang, Yungi, Kim, Tae Hyun, Kim, Dong-Sook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644069/
https://www.ncbi.nlm.nih.gov/pubmed/36386209
http://dx.doi.org/10.3389/fphar.2022.925287
_version_ 1784826666734845952
author Kim, Myojeong
Lee, GeunWoo
Hwang, Yungi
Kim, Tae Hyun
Kim, Dong-Sook
author_facet Kim, Myojeong
Lee, GeunWoo
Hwang, Yungi
Kim, Tae Hyun
Kim, Dong-Sook
author_sort Kim, Myojeong
collection PubMed
description Background: The Korean Pharmaceutical Information Service (KPIS) was established in October 2007 to increase the transparency of the pharmaceutical supply chain by integrating relevant information. This study aimed to describe the KPIS program and perform a cost-benefit analysis of the KPIS. Methods: We conducted a cost-benefit analysis based on cost savings in terms of National Health Insurance (NHI). The outcome measures were the net financial benefit and benefit-cost ratio over the 12 years since the establishment of the KPIS. The cost estimate included the costs of labor and business operations, the development of an information entry system, and office maintenance. Financial benefits were defined as savings resulting from the implementation of the program based on KPIS data. Social benefits were defined as the prevention of recalled medicines from entering the supply chain and the decrease in inventory and disposal. Results: The KPIS clearly resulted in a net financial benefit, saving 37.2 million USD, which was 2.6 times higher than the cost of implementation. While the benefit-cost ratio was less than one during the first period, it exceeded 3.4 during the second period. After calculating and integrating social benefits, the net benefit increased to 571.6 million USD, and the benefit-cost ratio was 24.8. A sensitivity analysis of the annual benefit showed that the net benefit varied from a low of −1.5 million USD to a high of 24.7 million USD according to the program implementation year. Conclusion: The establishment of the KPIS and a system for collecting information on the pharmaceutical supply chain showed meaningful financial and social benefits when compared to the input cost. Since no other countries have an integrated pharmaceutical information system that incorporates all information from production to administration, the example of the KPIS can provide a precedent for other countries.
format Online
Article
Text
id pubmed-9644069
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96440692022-11-15 Cost-benefit analysis of the integrated pharmaceutical supply chain information service after the establishment of the Korean Pharmaceutical Information Service Kim, Myojeong Lee, GeunWoo Hwang, Yungi Kim, Tae Hyun Kim, Dong-Sook Front Pharmacol Pharmacology Background: The Korean Pharmaceutical Information Service (KPIS) was established in October 2007 to increase the transparency of the pharmaceutical supply chain by integrating relevant information. This study aimed to describe the KPIS program and perform a cost-benefit analysis of the KPIS. Methods: We conducted a cost-benefit analysis based on cost savings in terms of National Health Insurance (NHI). The outcome measures were the net financial benefit and benefit-cost ratio over the 12 years since the establishment of the KPIS. The cost estimate included the costs of labor and business operations, the development of an information entry system, and office maintenance. Financial benefits were defined as savings resulting from the implementation of the program based on KPIS data. Social benefits were defined as the prevention of recalled medicines from entering the supply chain and the decrease in inventory and disposal. Results: The KPIS clearly resulted in a net financial benefit, saving 37.2 million USD, which was 2.6 times higher than the cost of implementation. While the benefit-cost ratio was less than one during the first period, it exceeded 3.4 during the second period. After calculating and integrating social benefits, the net benefit increased to 571.6 million USD, and the benefit-cost ratio was 24.8. A sensitivity analysis of the annual benefit showed that the net benefit varied from a low of −1.5 million USD to a high of 24.7 million USD according to the program implementation year. Conclusion: The establishment of the KPIS and a system for collecting information on the pharmaceutical supply chain showed meaningful financial and social benefits when compared to the input cost. Since no other countries have an integrated pharmaceutical information system that incorporates all information from production to administration, the example of the KPIS can provide a precedent for other countries. Frontiers Media S.A. 2022-10-26 /pmc/articles/PMC9644069/ /pubmed/36386209 http://dx.doi.org/10.3389/fphar.2022.925287 Text en Copyright © 2022 Kim, Lee, Hwang, Kim and Kim. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Kim, Myojeong
Lee, GeunWoo
Hwang, Yungi
Kim, Tae Hyun
Kim, Dong-Sook
Cost-benefit analysis of the integrated pharmaceutical supply chain information service after the establishment of the Korean Pharmaceutical Information Service
title Cost-benefit analysis of the integrated pharmaceutical supply chain information service after the establishment of the Korean Pharmaceutical Information Service
title_full Cost-benefit analysis of the integrated pharmaceutical supply chain information service after the establishment of the Korean Pharmaceutical Information Service
title_fullStr Cost-benefit analysis of the integrated pharmaceutical supply chain information service after the establishment of the Korean Pharmaceutical Information Service
title_full_unstemmed Cost-benefit analysis of the integrated pharmaceutical supply chain information service after the establishment of the Korean Pharmaceutical Information Service
title_short Cost-benefit analysis of the integrated pharmaceutical supply chain information service after the establishment of the Korean Pharmaceutical Information Service
title_sort cost-benefit analysis of the integrated pharmaceutical supply chain information service after the establishment of the korean pharmaceutical information service
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644069/
https://www.ncbi.nlm.nih.gov/pubmed/36386209
http://dx.doi.org/10.3389/fphar.2022.925287
work_keys_str_mv AT kimmyojeong costbenefitanalysisoftheintegratedpharmaceuticalsupplychaininformationserviceaftertheestablishmentofthekoreanpharmaceuticalinformationservice
AT leegeunwoo costbenefitanalysisoftheintegratedpharmaceuticalsupplychaininformationserviceaftertheestablishmentofthekoreanpharmaceuticalinformationservice
AT hwangyungi costbenefitanalysisoftheintegratedpharmaceuticalsupplychaininformationserviceaftertheestablishmentofthekoreanpharmaceuticalinformationservice
AT kimtaehyun costbenefitanalysisoftheintegratedpharmaceuticalsupplychaininformationserviceaftertheestablishmentofthekoreanpharmaceuticalinformationservice
AT kimdongsook costbenefitanalysisoftheintegratedpharmaceuticalsupplychaininformationserviceaftertheestablishmentofthekoreanpharmaceuticalinformationservice